STOCK TITAN

Avadel Pharmaceuticals plc Ordinary Share - AVDL STOCK NEWS

Welcome to our dedicated page for Avadel Pharmaceuticals plc Ordinary Share news (Ticker: AVDL), a resource for investors and traders seeking the latest updates and insights on Avadel Pharmaceuticals plc Ordinary Share stock.

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a specialty pharmaceutical company headquartered in Dublin, Ireland, with operations in St. Louis, Missouri, and Lyon, France. The company focuses on developing, identifying, and commercializing differentiated pharmaceutical products designed to be safe, effective, and easy to administer, thereby improving patient adherence and outcomes. Avadel's products primarily target the urology, central nervous system (CNS) / sleep, and hospital markets.

One of Avadel's flagship products is LUMRYZ™, an extended-release formulation of sodium oxybate, approved by the U.S. Food & Drug Administration (FDA) for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. LUMRYZ is notable for its once-at-bedtime dosing, which eliminates the need for a middle-of-the-night dose, making it more convenient for patients.

The FDA granted LUMRYZ seven years of Orphan Drug Exclusivity, recognizing it as a major contribution to patient care over existing therapies. The approval was supported by results from the REST-ON trial, a Phase 3 study that demonstrated significant improvements in EDS, the Clinician Global Impression of Improvement (CGI-I), and reduced the frequency of cataplexy attacks.

Avadel recently announced its financial results for the third quarter ended September 30, 2023, reporting $7.0 million in net product revenue from LUMRYZ sales. The company has seen robust demand and positive feedback from the narcolepsy community, healthcare providers, and payers. Notably, CVS Health has moved LUMRYZ to preferred status starting January 1, 2024. Avadel also filed a supplemental NDA to extend LUMRYZ's indication to pediatric patients with narcolepsy, further expanding its market reach.

Financially, Avadel reported a net loss of $36.3 million for the quarter, driven by higher selling, general, and administrative expenses related to the LUMRYZ launch. Despite these challenges, the company maintains a strong cash position of $153.2 million as of September 30, 2023.

Looking ahead, Avadel plans to issue its Annual Report on Form 10-K for the year ended December 31, 2023, on February 29, 2024. The company continues to focus on expanding its product pipeline, including initiating a Phase 3 trial for idiopathic hypersomnia and optimizing commercial execution for LUMRYZ.

Rhea-AI Summary

Avadel Pharmaceuticals (AVDL) reported strong Q2 2024 results, with $41.5 million in net revenue from LUMRYZ sales. The company saw significant growth in patient demand, with over 1,900 patients on LUMRYZ as of June 30th. Avadel is expanding its focus, having dosed the first patient in a Phase 3 trial for idiopathic hypersomnia and awaiting an FDA decision on LUMRYZ for pediatric narcolepsy by September 7, 2024.

Financial highlights include a gross profit of $38.7 million and a net loss of $13.8 million ($0.14 per diluted share). The company ended the quarter with $71.4 million in cash and equivalents. Avadel continues to invest in R&D and marketing efforts to support LUMRYZ's growth and potential new indications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
-
Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company, has announced it will host a conference call and live webcast on August 8, 2024, at 8:30 a.m. ET. The event will provide a corporate update and discuss the company's financial results for the second quarter ended June 30, 2024. Investors can access the live audio webcast through the company's website, www.avadel.com. A replay will be available for 90 days following the event. Participants are encouraged to register for the conference call in advance, at least 10 minutes prior to the start time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
-
Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) has announced the initiation of its Phase 3 REVITALYZ™ trial for LUMRYZ™ (sodium oxybate) in treating idiopathic hypersomnia (IH). The study, designed to evaluate the efficacy and safety of LUMRYZ as a once-at-bedtime dose, has dosed its first patient. The trial will enroll approximately 150 adults diagnosed with IH and includes an open-label extension.

The primary objective is to demonstrate reduced daytime sleepiness using the Epworth Sleepiness Scale (ESS) at Week 14. Secondary endpoints will assess additional efficacy parameters. Dr. Richard K. Bogan highlighted the significant unmet need in IH treatment, while Dr. Jennifer Gudeman emphasized the importance of this milestone for the IH community.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) will join the Russell 3000® Index following the 2024 Russell US Indexes annual reconstitution, effective July 1, 2024. This inclusion highlights Avadel's growth and market presence, providing enhanced visibility among investors. CEO Greg Divis expressed pride in this milestone and emphasized its potential to boost the company's commercial launch of LUMRYZ, aiming to create long-term shareholder value. The Russell 3000® Index encompasses the 4,000 largest US stocks by market capitalization, with Avadel's inclusion facilitating entry into either the Russell 2000® or Russell 1000® Index, along with relevant growth and value style indexes. The Russell indexes are key benchmarks for investment managers, with $10.5 trillion in assets benchmarked against them as of December 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
none
-
Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) has announced that its management will participate in two upcoming investor conferences. The company will join the Jefferies Global Healthcare Conference for a fireside chat on June 6 at 10:30 a.m. ET, and the Goldman Sachs 45th Annual Global Healthcare Conference for a fireside chat on June 12 at 3:20 p.m. ET. These events will be live-streamed and archived on Avadel's Investor Relations website for 90 days post-conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
conferences
-
Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) will present 11 posters and one oral presentation on LUMRYZ, an extended-release oral suspension for narcolepsy, at SLEEP 2024 from June 1-5 in Houston. LUMRYZ, FDA-approved in 2023, is the first once-nightly sodium oxybate for cataplexy and excessive daytime sleepiness (EDS). Key findings from the RESTORE study indicate 94% of patients prefer LUMRYZ over twice-nightly oxybate, with 91% reporting improved sleep quality and 89% likely to recommend it. Presentations will cover patient satisfaction, symptom control, dosing adherence, and demographic comparisons. The drug's boxed warning includes CNS depression and abuse potential. Common side effects are nausea, dizziness, enuresis, headache, and vomiting. The new data underscores LUMRYZ's effectiveness and patient preference in narcolepsy treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
none
Rhea-AI Summary

Avadel Pharmaceuticals announced the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, an executive with 30 years of global industry experience, currently serves as CEO of Orphalan SA. His background includes roles at Arix Bioscience, Advent Life Sciences, Smith and Nephew, Biogen Idec, Genzyme , and Baxter Healthcare. Dr. Amin joins Avadel as the company focuses on the commercial launch of LUMRYZ, a treatment for narcolepsy, and its potential expansion into pediatric and idiopathic hypersomnia markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.91%
Tags
management
-
Rhea-AI Summary

Avadel Pharmaceuticals reported strong financial results for the first quarter of 2024, generating $27.2 million in net revenue from LUMRYZ sales. The company enrolled over 2,800 patients in RYZUP patient support services, with more than 1,700 patients initiating therapy. Avadel is seeking to expand LUMRYZ usage through a sNDA for pediatric narcolepsy and plans to start a Phase 3 trial for idiopathic hypersomnia. Despite a net loss of $27.3 million, Avadel holds $88.8 million in cash and marketable securities as of March 31, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.62%
Tags
-
Rhea-AI Summary

Avadel Pharmaceuticals plc will host a conference call and live webcast on May 8, 2024, to provide a corporate update and discuss the financial results for the first quarter of 2024. Investors can access the call through dial-in numbers or the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
Rhea-AI Summary
Avadel Pharmaceuticals plc (AVDL) to participate in the 23rd Annual Needham Healthcare Conference with a fireside chat on April 8th. The event will be live webcasted and archived for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
conferences

FAQ

What is the current stock price of Avadel Pharmaceuticals plc Ordinary Share (AVDL)?

The current stock price of Avadel Pharmaceuticals plc Ordinary Share (AVDL) is $9.95 as of December 5, 2024.

What is the market cap of Avadel Pharmaceuticals plc Ordinary Share (AVDL)?

The market cap of Avadel Pharmaceuticals plc Ordinary Share (AVDL) is approximately 959.8M.

What is Avadel Pharmaceuticals plc?

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a specialty pharmaceutical company focused on developing differentiated pharmaceutical products for urology, CNS/sleep, and hospital markets.

What is LUMRYZ?

LUMRYZ is an extended-release formulation of sodium oxybate, approved by the FDA for treating cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. It is taken once at bedtime.

Where is Avadel Pharmaceuticals headquartered?

Avadel Pharmaceuticals is headquartered in Dublin, Ireland, with additional operations in St. Louis, Missouri, and Lyon, France.

What recent financial results did Avadel report?

For the third quarter ended September 30, 2023, Avadel reported $7.0 million in net product revenue from LUMRYZ sales and a net loss of $36.3 million.

What distinguishes LUMRYZ from other treatments?

LUMRYZ is the first and only once-at-bedtime oxybate treatment for narcolepsy, offering a more convenient dosing regimen compared to twice-nightly oxybate products.

What are the most common side effects of LUMRYZ?

The most common side effects include nausea, dizziness, bedwetting, headache, and vomiting.

What is the significance of LUMRYZ's Orphan Drug Exclusivity?

The FDA granted LUMRYZ seven years of Orphan Drug Exclusivity due to its significant contribution to patient care, providing a once-nightly dosing alternative to existing treatments.

How did the narcolepsy community respond to the launch of LUMRYZ?

The launch received overwhelmingly positive feedback, with early patient demand and significant support from healthcare providers and payers.

What other areas does Avadel Pharmaceuticals focus on?

In addition to narcolepsy, Avadel focuses on developing treatments for urology and hospital markets.

What are Avadel’s future plans for LUMRYZ?

Avadel plans to expand LUMRYZ's indication to pediatric patients and continue its Phase 3 trials for idiopathic hypersomnia.

Avadel Pharmaceuticals plc Ordinary Share

Nasdaq:AVDL

AVDL Rankings

AVDL Stock Data

959.76M
91.77M
4.77%
80.07%
9.15%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
DUBLIN